PTX3 and fungal infectious disease: Additionally, PTX3 has been identified as a low-cost/low-tech early biomarker for detecting secondary bacterial or fungal infections in COVID-19 patients (87), aiding in identification of individuals at high risk for community- or hospital-acquired infections and guiding an early antimicrobial therapy.